试验注册
KL0011034持续输注在健康中国成人中的安全性、药代动力学和药效学研究
Safety, Pharmacokinetics, and Pharmacodynamics of Continuous KL0011034 Infusion in Healthy Chinese Adults
作者：The Third Xiangya Hospital of Central South University
ClinicalTrials.gov · 2026年9月25日 · The Third Xiangya Hospital of Central S…
不需要生物学背景，多打比方
正在获取全文并生成讲解（拿不到全文就依据摘要）…
已等待 0 秒大约需要 10–20 秒
可以先看别的，做好了会自动出现在这里。
这篇还没有动画
动画会把研究的流程、作用机制和关键结果一步一步演示出来，每一步都标明出自原文哪里。制作大约需要一两分钟。
摘要Abstract
Brief summary: This Phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of continuous intravenous infusion of KL0011034 Injection in healthy Chinese adults. Approximately 30 participants will be enrolled in three sequential infusion-duration cohorts (1, 2, and 3 hours; 10 participants per cohort). Within each cohort, participants will be randomized in a 4:1 ratio to KL0011034 Injection or active-control propofol for anesthesia maintenance. All participants will receive propofol 2 mg/kg for anesthesia induction. Safety, pharmacokinetic, pharmacodynamic, recovery, and anesthesia-satisfaction assessments will be performed through 24 hours after dosing. Progression to the next infusion-duration cohort will occur only after the preceding cohort is considered safe and tolerable.
Conditions: Healthy Participants Study; General Anesthesia
Interventions: drug: KL0011034 Injection; drug: Propofol Injectable Emulsion
Phase: Phase 1
Enrollment: 30 (estimated)
Sponsor: The Third Xiangya Hospital of Central South University (other)
Status: not yet recruiting
还没有查过关联研究
我会去找这篇研究之前的基础工作、做类似事情的研究，以及之后引用它的研究，并说明每篇为什么相关。